Publicacións en colaboración con investigadores/as de Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico (15)

2024

  1. Decoding the historical tale: COVID-19 impact on haematological malignancy patients—EPICOVIDEHA insights from 2020 to 2022

    eClinicalMedicine, Vol. 71

2023

  1. Health-related quality of life following valoctocogene roxaparvovec gene therapy for severe hemophilia A in the phase 3 trial GENEr8-1

    Journal of Thrombosis and Haemostasis

  2. Molnupiravir compared to nirmatrelvir/ritonavir for COVID-19 in high-risk patients with haematological malignancy in Europe. A matched-paired analysis from the EPICOVIDEHA registry

    International Journal of Antimicrobial Agents, Vol. 62, Núm. 4

  3. Passive pre-exposure immunization by tixagevimab/cilgavimab in patients with hematological malignancy and COVID-19: matched-paired analysis in the EPICOVIDEHA registry

    Journal of hematology & oncology

  4. von Willebrand factor neutralizing and non-neutralizing alloantibodies in 213 subjects with type 3 von Willebrand disease enrolled in 3WINTERS-IPS

    Journal of Thrombosis and Haemostasis, Vol. 21, Núm. 4, pp. 787-799

2022

  1. Eltrombopag Added to Immunosuppression in Severe Aplastic Anemia

    New England Journal of Medicine, Vol. 386, Núm. 1, pp. 11-23

  2. Von Willebrand factor propeptide and pathophysiological mechanisms in European and Iranian patients with type 3 von Willebrand disease enrolled in the 3WINTERS-IPS study

    Journal of Thrombosis and Haemostasis, Vol. 20, Núm. 5, pp. 1106-1114

2020

  1. BAY 81-8973 demonstrated efficacy, safety and joint status improvement in patients with severe haemophilia A in the LEOPOLD I extension for ≤2 years

    European Journal of Haematology, Vol. 104, Núm. 6, pp. 594-601

  2. Bleeding symptoms in patients diagnosed as type 3 von Willebrand disease: Results from 3WINTERS-IPS, an international and collaborative cross-sectional study

    Journal of Thrombosis and Haemostasis, Vol. 18, Núm. 9, pp. 2145-2154

  3. Second cancers in MPN: Survival analysis from an international study

    American Journal of Hematology, Vol. 95, Núm. 3, pp. 295-301

2019

  1. Second cancer in Philadelphia negative myeloproliferative neoplasms (MPN-K). A nested case-control study

    Leukemia, Vol. 33, Núm. 8, pp. 1996-2005

2016

  1. Efficacy and safety of long-acting recombinant fusion protein linking factor IX with albumin in haemophilia B patients undergoing surgery

    Haemophilia, Vol. 22, Núm. 4, pp. e259-e266

2010

  1. ITER study of patients with haemo philia A and factor VIII inhibitors

    Hamostaseologie, Vol. 30, Núm. SUPPL.1, pp. 46-47

2007

  1. von Willebrand factor/factor VIII concentrate (Haemate® P) dosing based on pharmacokinetics: A prospective multicenter trial in elective surgery

    Journal of Thrombosis and Haemostasis, Vol. 5, Núm. 7, pp. 1420-1430

2002

  1. Graft-versus-host disease and outcome in HLA-identical sibling transplantations for chronic myeloid leukemia

    Blood, Vol. 100, Núm. 12, pp. 3877-3886